LONDON — NHS England has approved two innovative cancer medicines that will provide new treatment options for children and adults diagnosed with rare blood cancers, offering fresh hope to patients whose disease has not responded to existing therapies. Around 200 patients each year are expected to benefit from the new treatments.

The newly approved medicines include dabrafenib, a targeted therapy for histiocytic neoplasms, alongside another advanced treatment for eligible patients with rare blood cancers. NHS leaders say the approvals represent a significant step forward in delivering precision medicine, ensuring patients gain faster access to the latest clinically proven therapies.

Healthcare specialists believe the new treatments could improve survival prospects and quality of life for patients who previously had limited options. The approvals also reinforce the NHS's continued investment in innovative cancer care, with an increasing focus on personalised treatments based on the biology of individual diseases rather than traditional approaches alone.

Cancer charities have welcomed the decision, describing it as an important milestone for families affected by rare cancers. The move reflects the NHS's broader commitment to expanding access to cutting-edge medicines while supporting earlier diagnosis and better long-term outcomes for patients across England.